scispace - formally typeset
K

K. Robin Yabroff

Researcher at American Cancer Society

Publications -  304
Citations -  20791

K. Robin Yabroff is an academic researcher from American Cancer Society. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 58, co-authored 231 publications receiving 15084 citations. Previous affiliations of K. Robin Yabroff include United States Department of Health and Human Services & Georgetown University.

Papers
More filters
Journal ArticleDOI

Cancer treatment and survivorship statistics, 2019

TL;DR: Estimating cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau is presented.
Journal ArticleDOI

Projections of the Cost of Cancer Care in the United States: 2010–2020

TL;DR: The national cost of cancer care is substantial and expected to increase because of population changes alone, and the total cost in 2020 is projected to be $173 billion, which represents a 39% increase from 2010.
Journal ArticleDOI

Cost of Care for Elderly Cancer Patients in the United States

TL;DR: Net costs of care for elderly cancer patients in the United States for the 18 most prevalent cancers and for all other tumor sites combined are estimated and vary by tumor site, phase of care, stage at diagnosis, survival, and survival.
Journal ArticleDOI

Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.

TL;DR: Findings demonstrate that the health and economic burden of skin cancer treatment is substantial and increasing, and highlight the importance ofSkin cancer prevention efforts, which may result in future savings to the healthcare system.
Journal ArticleDOI

Burden of Illness in Cancer Survivors: Findings From a Population-Based National Sample

TL;DR: Cancer survivors have poorer health outcomes than do similar individuals without cancer across multiple burden measures and these decrements are consistent across tumor sites and are found in patients many years following reported diagnosis.